|Budget Amount *help
¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|Outline of Final Research Achievements
Gene sequences were analyzed in heterochronic cholangiocarcinomas by next-generation sequencing.In case 1, several gene mutations were identified in APC, CDKN2A, CDKN2B, CDKN1B, MDM2, CD274 and STK11 in the primary lesion and in APC, CDKN2A, CDKN2B, CDKN1B, MDM2, CD274, STK11, PTPRD, SMAD4, KEAP1, ARID1A, FBXW7 and PIK3R1 in the secondary lesion. In case 2, several variations were found in APC, TP53, JAK1, RB1, SMAD4 and AMER1 in the primary lesion and in APC, TP53, JAK1, RB1, SMAD4, AMER1, KRAS, CDKN2A and CDKN2B in the secondary lesion. The common mutations were those in APC, CDKN2A, CDKN2B and SMAD4 in both cases. New variations in the secondary lesion were detected, compared with those in the primary lesion, in heterochronic cholangiocarcinoma.
Further investigations will be required to clarify the malignant alterations. Our results are thought to be a clue for the development of novel methods for the diagnosis and therapy of cancer.